Pulmonary Arterial Hypertension
In patients with pulmonary arterial hypertension, endothelial colony forming cell transplantation was associated with restoration of myocardial vascular density.
LIQ861, an inhaled dry powder formulation of treprostinil, was well tolerated in patients with pulmonary arterial hypertension at a 2-week time point in the phase 3 clinical trial, INSPIRE.
Elevated levels of myocardial native T1 are associated with increased interventricular septal angle in patients with pulmonary hypertension.
PAH is an under-diagnosed complication of adult-onset Still disease.
Prognostic Relevance of Cardiopulmonary Exercise Testing in Low-Risk Pulmonary Arterial HypertensionJanuary 11, 2019
Combinations of VO2 and change in CI during follow-up visits are valuable prognosis markers in low-risk patients with PAH.
Systemic sclerosis-associated pulmonary hypertension and systemic sclerosis-associated interstitial lung disease exhibit similar but distinct gene expression profiles.
Treatment with treprostinil has demonstrated potential antithrombotic mechanisms of action in pediatric patients with pulmonary arterial hypertension.
Patients with pulmonary hypertension age ≥65 years have worse long-term survival compared with younger patients.
The time course of pulmonary arterial hypertension was an independent risk factor for pulmonary artery aneurysms.
People with pulmonary arterial hypertension display higher levels of depression and anxiety than previously estimated by healthcare workers.
Because standardized approaches for echocardiographic screening are impractical for certain subgroups of people with congenital heart disease, experts offered screening adaptations for pulmonary hypertension.
Pulmonary thromboendarterectomy appears to be a curative resolution in patients with antiphospholipid syndrome related to chronic thromboembolic pulmonary hypertension.
Factors associated with a higher risk for mortality included male sex, exercise desaturation, and diffusing capacity of the lungs for carbon monoxide <50%.
At follow-up, the 6-minute walk distance, cardiac index, stroke volume index, and other hemodynamic variables were independently associated with transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension.
Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.
Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.
Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.
United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.
Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.
A number of risk factors were associated with chronic thromboembolic pulmonary hypertension, including, age >70 years, female gender, and pulmonary embolism at first venous thromboembolism.
Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.
Neopterin was predictive of clinical deterioration in patients with pulmonary arterial hypertension and inoperable CTEPH.
Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.
Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.
Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.
A 72-year-old man with hypertension and paroxysmal atrial fibrillation presents to the emergency department because he has been experiencing worsening shortness of breath.
The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.
The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.
Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.